Literature DB >> 26801344

An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer.

Shuichi Takano1, Hiroaki Saito2, Masahide Ikeguchi1.   

Abstract

PURPOSE: Co-signaling molecules play an important role in T cells. This study was designed to investigate PD-1 and Tim-3 expression on T cells and the relationships between PD-1 and Tim-3 expression and immune evasion in patients with gastric cancer.
METHODS: Using multicolor flow cytometry, we analyzed PD-1 and Tim-3 expression on CD8+ T cells obtained from peripheral blood mononuclear cells (PBMCs) and gastric cancer tissue.
RESULTS: Significantly more PD-1+ and Tim-3+ CD8+ T cells in peripheral blood were found in gastric cancer patients than in healthy controls. PD-1+ CD8+ T cells were significantly correlated with Tim-3+ CD8+ T cells in peripheral blood from the gastric cancer patients (r = 0.29, p = 0.036). Furthermore, significantly greater numbers of PD-1+ and Tim-3+ CD8+ T cells were seen in the gastric cancer tissue samples than in the PBMCs. CD8+ T cells positive for both PD-1 and Tim-3 produced significantly less IFN-gamma than cells negative for both and cells positive for PD-1 and negative for Tim-3.
CONCLUSION: An increased number of PD-1+ and Tim-3+ CD8+ T cells is closely related to impaired function of CD8+ T cells in gastric cancer patients.

Entities:  

Keywords:  Gastric cancer; PD-1; T cell; Tim-3

Mesh:

Substances:

Year:  2016        PMID: 26801344     DOI: 10.1007/s00595-016-1305-9

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  34 in total

Review 1.  Immunostimulatory monoclonal antibodies for cancer therapy.

Authors:  Ignacio Melero; Sandra Hervas-Stubbs; Martin Glennie; Drew M Pardoll; Lieping Chen
Journal:  Nat Rev Cancer       Date:  2007-02       Impact factor: 60.716

2.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.

Authors:  Laurent Monney; Catherine A Sabatos; Jason L Gaglia; Akemi Ryu; Hanspeter Waldner; Tatyana Chernova; Stephen Manning; Edward A Greenfield; Anthony J Coyle; Raymond A Sobel; Gordon J Freeman; Vijay K Kuchroo
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

3.  Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.

Authors:  Junko Matsuzaki; Sacha Gnjatic; Paulette Mhawech-Fauceglia; Amy Beck; Austin Miller; Takemasa Tsuji; Cheryl Eppolito; Feng Qian; Shashikant Lele; Protul Shrikant; Lloyd J Old; Kunle Odunsi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

4.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

Authors:  H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo
Journal:  Science       Date:  2001-01-12       Impact factor: 47.728

5.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

6.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

Review 7.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.

Authors:  Arlene H Sharpe; E John Wherry; Rafi Ahmed; Gordon J Freeman
Journal:  Nat Immunol       Date:  2007-03       Impact factor: 25.606

8.  PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues.

Authors:  Mary E Keir; Gordon J Freeman; Arlene H Sharpe
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

9.  Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells.

Authors:  Lucy Golden-Mason; Brent E Palmer; Nasim Kassam; Lisa Townshend-Bulson; Stephen Livingston; Brian J McMahon; Nicole Castelblanco; Vijay Kuchroo; David R Gretch; Hugo R Rosen
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

10.  Dysregulated T cell expression of TIM3 in multiple sclerosis.

Authors:  Ken Koguchi; David E Anderson; Li Yang; Kevin C O'Connor; Vijay K Kuchroo; David A Hafler
Journal:  J Exp Med       Date:  2006-06-05       Impact factor: 14.307

View more
  15 in total

1.  The accumulation of regulatory T cells in the hepatic hilar lymph nodes in biliary atresia.

Authors:  Naoya Sakamoto; Toshihiro Muraji; Haruo Ohtani; Kouji Masumoto
Journal:  Surg Today       Date:  2017-03-14       Impact factor: 2.549

Review 2.  Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights.

Authors:  Sandeep Kumar; Sunil Kumar Singh; Basabi Rana; Ajay Rana
Journal:  Drug Discov Today       Date:  2021-01-12       Impact factor: 8.369

Review 3.  Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer.

Authors:  Xiaojun Liu; Zhongxia Yang; Olivier Latchoumanin; Liang Qiao
Journal:  Therap Adv Gastroenterol       Date:  2016-07-21       Impact factor: 4.409

4.  Tim-3 and PD-1 regulate CD8+ T cell function to maintain early pregnancy in mice.

Authors:  Yuan-Yuan Xu; Song-Cun Wang; Yi-Kong Lin; Da-Jin Li; Mei-Rong DU
Journal:  J Reprod Dev       Date:  2017-03-23       Impact factor: 2.214

5.  RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.

Authors:  Dennis C Harrer; Bianca Simon; Shin-Ichiro Fujii; Kanako Shimizu; Ugur Uslu; Gerold Schuler; Kerstin F Gerer; Stefanie Hoyer; Jan Dörrie; Niels Schaft
Journal:  BMC Cancer       Date:  2017-08-17       Impact factor: 4.430

6.  Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer.

Authors:  Yoshitaro Shindo; Shoichi Hazama; Nobuaki Suzuki; Haruo Iguchi; Kazuhiro Uesugi; Hiroaki Tanaka; Atsushi Aruga; Takashi Hatori; Hidenobu Ishizaki; Yuzo Umeda; Toshiyoshi Fujiwara; Tetsuya Ikemoto; Mitsuo Shimada; Kazuhiko Yoshimatsu; Hiroko Takenouchi; Hiroto Matsui; Shinsuke Kanekiyo; Michihisa Iida; Yasunobu Koki; Hideki Arima; Hiroyuki Furukawa; Tomio Ueno; Shigefumi Yoshino; Tomonobu Fujita; Yutaka Kawakami; Yusuke Nakamura; Masaaki Oka; Hiroaki Nagano
Journal:  J Exp Clin Cancer Res       Date:  2017-02-28

7.  Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer.

Authors:  An Na Seo; Byung Woog Kang; Oh Kyoung Kwon; Ki Bum Park; Seung Soo Lee; Ho Young Chung; Wansik Yu; Han Ik Bae; Seong Woo Jeon; Hyojeung Kang; Jong Gwang Kim
Journal:  Br J Cancer       Date:  2017-10-26       Impact factor: 7.640

8.  Tumor-infiltrating CD4+ T cells in patients with gastric cancer.

Authors:  Long Yuan; Benling Xu; Peng Yuan; Jinxue Zhou; Peng Qin; Lu Han; Guangyu Chen; Zhenlei Wang; Zengci Run; Peng Zhao; Quanli Gao
Journal:  Cancer Cell Int       Date:  2017-12-02       Impact factor: 5.722

9.  STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion.

Authors:  Jung-Mao Hsu; Weiya Xia; Yi-Hsin Hsu; Li-Chuan Chan; Wen-Hsuan Yu; Jong-Ho Cha; Chun-Te Chen; Hsin-Wei Liao; Chu-Wei Kuo; Kay-Hooi Khoo; Jennifer L Hsu; Chia-Wei Li; Seung-Oe Lim; Shih-Shin Chang; Yi-Chun Chen; Guo-Xin Ren; Mien-Chie Hung
Journal:  Nat Commun       Date:  2018-05-15       Impact factor: 14.919

Review 10.  Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.

Authors:  Emily M Lin; Jun Gong; Samuel J Klempner; Joseph Chao
Journal:  World J Gastroenterol       Date:  2018-07-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.